# Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

> **NCT00578292** · NA · TERMINATED · sponsor: **Baylor College of Medicine** · enrollment: 10 (actual)

## Conditions studied

- Thalassemia

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **DRUG:** Campath 1H
- **DRUG:** Cyclophosphamide
- **DRUG:** MESNA

## Key facts

- **NCT ID:** NCT00578292
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Stem cell transplant was determined SOC for this disease (study is not relevant)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00578292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00578292, "Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00578292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*